Seeneuro Medical Closes Hundreds of Millions of yuan Series B Financing

Hangzhou, China-based Seeneuro Medical has closed hundreds of millions of yuan series B financing led by OrbiMed Capital and followed by the existing investor BioTrack Capital, for the research and development, clinical trials, and commercialization of its implantable neurostimulators and brain-computer interface medical devices.

Since its inception in December 2018, Seeneuro Medical owns nearly thirty patented technologies and has successfully developed products such as spinal cord stimulator (SCS) and short-term implantable peripheral nerve stimulator, and will develop new products including fully implantable peripheral neurostimulators, and autonomic nerve stimulators.

With its leading technology platform, Seeneuro Medical has a number of key products in late stage clinical development with excellent trial data. We are excited to partner with Seeneuro Medical to provide Chinese and global patients with a range of more effective and accessible neuromodulation therapeutic products for a variety of disease areas,” said Dr David Wang, Partner at OrbiMed Capital.

en_GBEnglish (UK)